无症状慢性阻塞性肺疾病患者早期干预的临床研究

Clinical Study on Early Intervention in Patients with Asymptomatic Chronic Obstructive Pulmonary Disease

目的研究无症状慢性阻塞性肺疾病(COPD)患者早期干预的临床意义。方法选取我院2017年1月至2017年12月期间确诊为COPD的Ⅰ级和Ⅱ级患者60例,随机分为治疗组和对照组,每组30例。治疗组吸入噻托溴铵18μg/次,每日1次,对照组按需吸入短效支气管扩张剂,两组患者均治疗6个月。比较两组患者治疗前后的FEV_1、 FVC以及FEV_1/FVC%水平。结果治疗前,两组患者的FEV_1、 FVC和FEV_1/FVC%水平比较差异均无统计学意义(P>0.05);治疗后,两组患者的FEV_1、FVC和FEV_1/FVC%水平均有所改善,治疗组的FEV_1、 FVC和FEV_1/FVC%水平均明显优于对照组,差异均有统计学意义(P <0.05)。结论使用长效支气管扩张剂噻托溴铵对无症状COPD患者进行早期干预治疗,能够延缓肺功能的下降,甚至改善肺功能情况,值得临床推广。

Objective To study the clinical significance of early intervention in patients with asymptomatic chronic obstructive pulmonary disease（COPD）. Methods 60 cases of patients diagnosed as grade Ⅰ and grade Ⅱ COPD in our hospital from January 2017 to December 2017 were selected and randomly divided into treatment group and control group, with 30 cases in each group. The treatment group inhaled 18 μg/time of tiotropium bromide for once a day, while the control group inhaled short-acting bronchodilator on demand.Both groups were treated for 6 months, The FEV1, FVC and FEV1/FVC% levels before and after treatment were compared between the two groups. Results Before treatment, no statistical difference was found in the FEV1, FVC and FEV1/FVC% levels between the two groups（P0.05）. After treatment, the FEV1, FVC and FEV1/FVC% levels both groups improved（P 0.05）, and the FEV1, FVC and FEV1/FVC%levels of the treatment group were significantly better than those of the control group（P 0.05）. Conclusions Long-term bronchodilator tiotropium in the early intervention of patients with asymptomatic COPD can delay the decline of pulmonary function and even improve the pulmonary function, which is worthy of clinical promotion.